Stock search

Ticker or company name

Compare stocks

Market: US

  • REGNRegeneron Pharmaceuticals

Add stock

Ticker or company

Summary

REGN
Regeneron Pharmaceuticals
$952,40Down −0,32%
Year: Up +37%
67/100Ratio would watch
Open stock page

Traffic light — 10 checks

CheckREGN5 ✓ 2 — 2 ✕
P/E vs its history20,5
P/E vs industry20,5
Forward P/E13,8
Revenue growth, YoY+18,6%
EPS growth, YoY+8,3%
Net margin28,5%
Net debt / EBITDA−1,4
Free cash flow$3,83 bn
Share count over a year−1,5%
Cash runwayn/anot needed

Metrics

Best WorstNo mark — in between

Metric · betterREGNTTMIndustry medianTTM
P/E TTM ↓20,542,1
Forward P/E ↓13,818,7
PEG ↓1,24,1
P/S TTM ↓5,86,6
EV/EBITDA ↓18,228,2
P/FCF ↓27,226,0

Price, %

  • REGNn/a

Returns

Best WorstNo mark — in between

PeriodREGN
1 yearn/a
3 yearsn/a
5 yearsn/a
All timen/a

“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.

Analysts and insiders

Best WorstNo mark — in between

REGN
Share of “buy”72%
Beat the forecast4 of 4
Average “surprise”+16,8%
Insiders over 12 monthssales $57,9 m

Details are on each stock page.